Inactive Instrument
Antibe Therapeutics Inc. Share Price
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/04/24 | Antibe Announces Appointment of Receiver | BU |
| 22/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 16/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 30/11/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 08/03/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 08/03/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 08/03/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| -2.11% | -1.68% | +43.40% | +95.58% | 66.93B | |
| +1.76% | -0.05% | +36.21% | +77.06% | 61.97B | |
| -3.43% | +0.31% | -12.48% | +369.74% | 28.26B | |
| +4.55% | -0.08% | +34.70% | +17.28% | 24.59B | |
| +2.79% | +0.07% | +0.87% | -13.25% | 24.3B | |
| +1.15% | -1.03% | +19.11% | -21.81% | 19.41B | |
| -7.03% | -9.16% | +161.91% | +303.00% | 16.77B | |
| +3.44% | -1.68% | -5.00% | +541.17% | 14.18B | |
| +5.16% | +6.71% | -2.64% | +865.45% | 14B | |
| Average | +0.64% | -4.27% | +30.68% | +248.25% | 30.05B | |
| Weighted average by Cap. | +0.29% | -3.56% | +31.98% | +170.75% |
Employees
11
